433289-68-0Relevant academic research and scientific papers
De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold
Potin, Dominique,Launay, Michele,Nicolai, Eric,Fabreguette, Maud,Malabre, Patrice,Caussade, Francois,Besse, Dominique,Skala, Stacey,Stetsko, Dawn K.,Todderud, Gordon,Beno, Brett R.,Cheney, Daniel L.,Chang, Chiehying J.,Sheriff, Steven,Hollenbaugh, Diane L.,Barrish, Joel C.,Iwanowicz, Edwin J.,Suchard, Suzanne J.,Dhar, T. G. Murali
, p. 1161 - 1164 (2007/10/03)
LFA-1 (leukocyte function-associated antigen-1), is a member of the β2-integrin family and is expressed on all leukocytes. The LFA-1/ICAM interaction promotes tight adhesion between activated leukocytes and the endothelium, as well as between T cells and antigen-presenting cells. Evidence from both animal models and clinical trials provides support for LFA-1 as a target in several different inflammatory diseases. This paper describes the de novo design, synthesis and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold.
Hydantoin compounds useful as anti-inflammatory agents
-
, (2008/06/13)
Compounds having the formula (I): 1and pharmaceutically-acceptable salts thereof, are useful for treating inflammatory or immune diseases, in which A is a four to seven membered heterocyclic or carbocyclic saturated ring; L and K are O or S; M is N or CH; Y is N or CH; Z is hydrogen, alkyl or substituted alkyl; and R1-R4 are as defined in the specification.
